NCT05938478View on ClinicalTrials.gov

Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

RecruitingOBSERVATIONAL
Enrollment

900

Participants

Timeline

Start Date

December 8, 2022

Primary Completion Date

November 30, 2034

Study Completion Date

September 30, 2035

Conditions
Atopic DermatitisEczema
Interventions
DRUG

Tralokinumab

This is a prospective observational cohort study. There is no treatment allocation. Participants that have been exposed to tralokinumab before enrollment into the study will be enrolled.

Trial Locations (1)

92093

RECRUITING

University of California San Diego (UCSD), La Jolla

Sponsors

Collaborators (1)

LEO Pharma
All Listed Sponsors
collaborator

LEO Pharma

INDUSTRY

collaborator

The Organization of Teratology Information Specialists

OTHER

lead

University of California, San Diego

OTHER

NCT05938478 - Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT | Biotech Hunter | Biotech Hunter